| 000 | 01408 a2200385 4500 | ||
|---|---|---|---|
| 005 | 20250515040410.0 | ||
| 264 | 0 | _c20061109 | |
| 008 | 200611s 0 0 eng d | ||
| 022 | _a0043-5341 | ||
| 024 | 7 |
_a10.1007/s10354-006-0312-7 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aZollner, Gernot | |
| 245 | 0 | 0 |
_aMolecular mechanisms of cholestasis. _h[electronic resource] |
| 260 |
_bWiener medizinische Wochenschrift (1946) _cJul 2006 |
||
| 300 |
_a380-5 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aATP-Binding Cassette Transporters _xgenetics |
| 650 | 0 | 4 |
_aBile Acids and Salts _xmetabolism |
| 650 | 0 | 4 |
_aBilirubin _xmetabolism |
| 650 | 0 | 4 |
_aCholestasis, Intrahepatic _xdrug therapy |
| 650 | 0 | 4 | _aDNA Mutational Analysis |
| 650 | 0 | 4 |
_aHepatocytes _xmetabolism |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInactivation, Metabolic _xgenetics |
| 650 | 0 | 4 |
_aLiver _xmetabolism |
| 650 | 0 | 4 |
_aMembrane Transport Proteins _xgenetics |
| 650 | 0 | 4 |
_aReceptors, Cytoplasmic and Nuclear _xgenetics |
| 650 | 0 | 4 |
_aRifampin _xtherapeutic use |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 | _aSyndrome |
| 650 | 0 | 4 |
_aUrsodeoxycholic Acid _xtherapeutic use |
| 700 | 1 | _aTrauner, Michael | |
| 773 | 0 |
_tWiener medizinische Wochenschrift (1946) _gvol. 156 _gno. 13-14 _gp. 380-5 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s10354-006-0312-7 _zAvailable from publisher's website |
| 999 |
_c16522615 _d16522615 |
||